Produced by Mundipharma, BETADINE® has a track record of over 50 years in providing broad spectrum antiseptics to consumers in the categories of wound care, oral and female hygiene, among others. Betadine® Antiseptics are widely used in hospitals, doctors’ surgeries, sports medicine clinics and veterinarian clinics. A real advantage of the Betadine® range is its key ingredient povidone-iodine, which has the power of traditional iodine but does not sting or irritate nearly as much1. The Betadine® range uses the powerful action of iodine against a range of bacteria, viruses and fungi 2-3.
||Hydrogel with Povidone-Iodine (3%) and Liposomal Delivery System
THE PRODUCT RANGE INCLUDES:
BETADINE® has three main categories of products with over 10 different formats to meet the varying needs of our customers.
BETADINE® ORAL CARE rapidly kills the three groups of organisms that cause throat infections – bacteria, viruses, and fungi, in as fast as 30 seconds 4 . It is effective in killing the viruses that cause avian flu, common flu, and common colds4-6.
BETADINE® FEMININE CARE
BETADINE® has effective medicated products for treating a wide range of vaginal infections. By killing germs such as bacteria, fungi, and protozoa which cause vaginal infection, BETADINE® helps relieve vaginal infection symptoms such as vaginal discomfort, abnormal discharge, odour and itchiness7-10.
For more than 50 years, BETADINE® products have found widespread acceptance in hospitals and homes around the world as an important first line of defense against topical infections. Over the years, the brand’s portfolio has grown to offer a complete range of antiseptic solutions that address the specialized requirements of doctors and households.
The origins of BETADINE® dates back to 1952 and the creation of this new treatment was significant as it represented the next major improvement in medicinal iodine compounds in the last 100 years.
Iodine is an age old antiseptic. However, by itself it does not dissolve in water and can be unstable. Traditionally, pharmacists had to add up to 70% of alcohol to create medications. The high content of alcohol posed a problem as it slowed down the rate of healing for wounds.
A new, safe, easy to handle and effective treatment was born with the addition of PVP that got rid of the alcohol. This marked the beginnings of the BETADINE® success story. Today, PVP-I is a high-quality iodine owned by BETADINE® that is distributed and sold globally.
BETADINE Dry Powder Spray is a new, easier way to treat minor wounds at home. It’s no touch, no drip and easy to carry – giving mothers the confidence to deal with any emergency easily.
Povidone-iodine preparation, an upgraded iodine based antiseptic formulation, was discovered. Its slow release of iodine within the formula was found to improve product stability, reduce the sting and irritation of traditional iodine treatments. It quickly became the universally preferred iodine disinfectant.
BETADINE® is registered as a trademark and launched in several international markets.
BETADINE® antiseptic was chosen by NASA to wipe down the Apollo 11 spacecraft when it landed back on earth after a successful trip to the moon to remove any space germs that might have hitched a ride.
® Betadine is registered trademarks of Mundipharma AG in UAE and is either registered trademark or trademark in other countries.
Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities
* Not all products or indications are available in all countries. Products are currently under registrations across Middle East, Turkey and Africa Region and subject to approval according to local laws and regulations.
Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for readers from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.
1. Healthcare Infection Control Practices Advisory Committee (HICPAC) US CDC Guideline for disinfection and sterilization in healthcare facilities, 2008.
2. Mayer DA, et al. Wounds: A Compendium of Clinical Research and Practice. 1993; 5(1): 14-23
3. Kawana R et al. Dermatology 1997;195(suppl 2)29-35.
4. Beaton et al. Int. J. Fertil 29(2), 1984, p. 109-112
5. Monif GR, et al. Am J Obstet Gynecol. 1980;137:432–438
6. Gunther WewaIka et al. Dermatology 2002; 204(suppl 1): 79-85
7. S Maneksha. J Int Med Res 1974; 2: 236-239
8. Kawana R et al. Dermatology 1997;195(suppl 2)29-35.
9. Sriwilaijaroen N, et al. Virology Journal 2009;6:124.
10. Kariwa H, et al. Dermatology 2004; 212(suppl 1): 119-123.